This study was published in the Journal of the American College of Cardiology 1997 Oct;30(4):863-9
Study title and authors:
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM.
Division of Cardiology B, Hôpital Cardiologique, Lille, France. bertrandme@AOL.com
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/9316510
This study investigated the effects of pravastatin treatment after coronary balloon angioplasty. (Coronary angioplasty is accomplished using a balloon-tipped catheter inserted through an artery in the groin or arm to enlarge a narrowing in a coronary artery). In a multicenter, randomized, double-blind trial, 695 patients were randomized to receive pravastatin (40 mg/day) or placebo for 6 months after successful balloon angioplasty.
The study found that the patients on statin treatment had a 301% increased risk of death compared to the patients receiving placebo.